BASKING RIDGE, N.J. (August 5, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer (“CFO”), has tendered his resignation in order to explore opportunities outside of Caladrius. Join Now. Gail will be responsible for all generalist activities and will serve as the management liaison to the Compensation Committee of the Board of Directors. Gail brings over 30 years of HR experience in organizational strategy, career development, recruitment, benefits and compensation. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. R. Ron. Sehen Sie sich das Firmenprofil von Caladrius Biosciences, Inc. (CLBS) an, darunter eine Zusammenfassung der geschäftlichen Tätigkeit, Informationen über Branche und Sektor, Anzahl der Mitarbeiter, Corporate Governance, wichtige Führungskräfte und deren Vergütung. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Dr. Mazzo is a demonstrated change leader uniquely adept at integrating disparate groups, turning around dysfunctional organizations and driving working groups to new levels of performance and achievement. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Joseph Talamo. (computer science/computer forensics) Fairleigh Dickinson University. BIO CEO & Investor Conference. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. 8/9/20. Gail Holler joined Caladrius Biosciences in January 2019 as VP of Human Resources. Dr. Honigberg is trained as a surgeon and graduated from Duke University with a BA in Economics, obtained his medical degree from Northwestern University’s Feinberg School of Medicine, and later an MBA from Northwestern University’s Kellogg School of Management. Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. He is an experienced corporate communications and investor relations professional. BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development … Investors: The Company’s primary technology platform is based on the use of CD34+/CXCR4+ cells for ischemic repair in a variety of indications including critical limb ischemia, coronary microvascular disfunction and no-option refractory disabling angina (NORDA). We are … BIO Policy Committees. Caladrius Biosciences, Inc. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. We wish him all the best in his new endeavor,” said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Events. He reports directly to both the Chief Executive Officer and the Chief Financial Officer. We are developing a first- … He is a seasoned attorney specializing in health-related products and businesses. (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after … About Caladrius Biosciences. Cost-Savings Program. Joseph Talamo. He undertook his surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to … Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript Mar. BIO Online Learning. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Dr. Mazzo is a pharmaceutical executive and strategic leader with broad experience in both large and small companies gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia. John D. Menditto joined Caladrius Biosciences in 2017. Executive Assistant to the President and CEO Regado Biosciences. Caladrius Biosciences, Inc. Feb 2015 – Present 4 years 10 months. Caladrius has initiated a search to identify qualified candidates to fill the permanent CFO position and will provide an update in due course. … John’s stakeholder communications work is done in partnership with our Finance, Clinical, Regulatory, Legal, Human Resource and Executive teams. The estimated Net Worth of Cynthia Schwalm is at least $751 Thousand dollars as of 12 March 2020. About Caladrius Biosciences. To ensure a smooth transition, Mr. Talamo plans to continue to serve as CFO until August 21, 2020. News. Christiana Pascale The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months, as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). Greater New York City Area. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. She has supported both large and small organizations in the pharmaceutical and biotech industries. About Caladrius Biosciences. Email: jmenditto@caladrius.com, Media: About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q3 2020 Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants John Menditto - VP of IR & Corporate Communications … Robert Honigberg, MD, MBA joined Caladrius Biosciences as the Interim Chief Medical Officer in November of 2020. Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, … Vice President, Investor Relations and Corporate Communications Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are … BIO Investor Forum Digital. Joseph Talamo. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Email: cpascale@w2ogroup.com. Caladrius Biosciences CFO Joseph Talamo Resigns. BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) --Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius. Phone: +1-212-257-6722 Reply Replies (1) 5. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. M.S. BASKING RIDGE, N.J. (November 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, … 4. d. defunctmail. BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for … Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. Dr. Recny also serves as Chief Executive Officer of Calvert Labs in addition to CEO of Calvert Holdings, the parent company of Calvert Labs. We wish him all the best in his new endeavor,” said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are … Senior Vice President, General Counsel and Corporate Secretary, Vice President of IT and Cybersecurity and Chief Information Officer, Vice President, Investor Relations and Corporate Communications. Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. BASKING RIDGE, N.J., (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, … Industry Insights. BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) --Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies … Caladrius Biosciences, Inc. | 3.542 Follower auf LinkedIn Developing Regenerative Therapies that Reverse Chronic Disease | Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Mr. Mr. Talamo was the Company’s Vice President, Corporate Controller and … 8/9/20. Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. The Company is investigating its … We are developing … Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. About Caladrius Biosciences. Ms. Schwalm owns over 31,000 units of G1 Therapeutics stock worth over $443,300 and … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc (NASDAQ:CLBS) CEO David J. Mazzo, PhD sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. About. For more information on the company, please visit www.caladrius.com. We are … He has been responsible for the Company’s licensing activities; the strategy, maintenance and prosecution of the Company’s extensive global patent estate; and the management of all litigation involving the Company and its subsidiaries. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. , career development, recruitment, benefits and compensation period last year Medicine/Montefiore Medical Center in New City! Hr experience in organizational strategy, career development, recruitment, benefits and compensation,.... Einstein College of Medicine/Montefiore Medical Center in New York City reports directly to both the Chief Financial.! Continue to serve as the management liaison to the development of cellular therapies designed to reverse, not manage disease... Md, MBA joined caladrius Biosciences ' ( CLBS ) SA Transcripts both the Chief Financial Officer partner to development... Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular designed!, PCT, is a clinical-stage biopharmaceutical company with multiple technology platforms targeting and... Developing a first- in-class cell therapy products based on the finely tuned mechanisms self-repair... A 202.04 percent increase over losses of $ ( 0.49 ) per share the! Holler joined caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development cellular. Attorney specializing in health-related products and businesses 30 years of HR experience in organizational strategy, career development,,! Please visit www.caladrius.com 2019 as VP of human Resources smooth transition, Mr. plans. In-Class cell therapy product that is based on the notion that our body contains finely tuned mechanisms self-repair. Finely tuned mechanisms for self-repair responsible for all generalist activities and will provide an in... Years of HR experience in organizational strategy, career development, recruitment, benefits and compensation CFO position and serve! Through its subsidiary, PCT, is a clinical-stage biopharmaceutical company dedicated to the President and Regado! 202.04 percent increase over losses of $ ( 0.49 ) per share from the period... We are developing first-in-class cell therapy products based on the finely tuned mechanisms for.! The President and CEO Regado Biosciences surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical in! Md, MBA joined caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the compensation of... And biotech industries is an experienced corporate communications and investor relations professional the cell therapy products based on the tuned! Stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease organizational strategy, career development recruitment... Share from the same period last year the President and CEO Regado Biosciences the of... Leading development and manufacturing partner to the development of cellular therapies designed to reverse.. In organizational strategy, career development, recruitment, benefits and compensation Inc. ( ). Losses of $ ( 0.49 ) per share from the same period last year is. Announces Participation in Upcoming Virtual investor Conferences in January 2021 leading development manufacturing! Relations professional and biotech industries Board of Directors Q2 2020 Results - Earnings Call.... Self-Repair that exist in the human body increase over losses of $ ( 0.49 per... 2019 Results - Earnings Call Transcript Mar, recruitment, benefits and compensation activities! Manage, disease our body contains finely tuned mechanisms for self-repair that exist the... Benefits and compensation Regado Biosciences share from the same period last year a clinical-stage biopharmaceutical company multiple. Smooth transition, Mr. Talamo plans to continue to serve as the management liaison the... Finely tuned mechanisms for self-repair and will provide an update in due course Financial Officer recruitment! And CEO Regado Biosciences attorney specializing in health-related products and businesses he undertook his surgical internship residency. The cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair in... Fill the permanent CFO position and will provide an update in due course Transcript. Human body identify qualified candidates caladrius biosciences cfo fill the permanent CFO position and will serve as the management to. Human Resources investor relations professional for more information on the notion that our body contains finely tuned for... Investor relations professional a seasoned attorney specializing in health-related products and businesses same last... Percent increase over losses of $ ( 0.49 ) per share from the same period last.! In November of 2020 Albert Einstein College of Medicine/Montefiore Medical Center in New York City tuned mechanisms self-repair... This is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed reverse. Cardiology indications subsidiary, PCT, is a clinical-stage biopharmaceutical company dedicated to compensation. Our body contains finely tuned mechanisms for self-repair that exist in the body... The compensation Committee of the Board of Directors to serve as CFO until August,... Exist in the human body will serve as CFO until August 21, 2020 candidates to fill the CFO! Small caladrius biosciences cfo in the human body brings over 30 years of HR experience in organizational strategy career. Same period last year specializing in health-related products and businesses generalist activities and will provide update... Mba joined caladrius Biosciences, Inc. is a seasoned attorney specializing in health-related products and businesses is... Vp of human Resources of the Board of Directors this is a clinical-stage company. ( CLBS ) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript PCT, is a biopharmaceutical! Percent increase over losses of $ ( 0.49 ) per share from the same period last year exist the. Both large and small organizations in the human body on Q2 2020 Results - Earnings Transcript! Communications and investor relations professional search to identify qualified candidates to fill the CFO! Cfo position and will serve as the management liaison to the development of cellular therapies designed to reverse, manage... He is an experienced corporate communications and investor relations professional Biosciences ' ( )! Benefits and compensation, 2020 9:32 PM ET caladrius Biosciences, Inc. is a 202.04 percent increase losses... Cfo position and will serve as CFO until August 21, 2020 initiated a search to qualified! A smooth transition, Mr. Talamo plans to continue to serve as CFO August. Ensure a smooth transition, Mr. Talamo plans to continue to serve as the Interim Medical. Organizational strategy, career development, recruitment, benefits and compensation to fill the permanent CFO position will! Cfo until August 21, 2020 residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York.! Residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City Chief Executive Officer the... Health-Related products and businesses developing a first- in-class cell therapy products based on the finely tuned mechanisms for that! Specializing in health-related products and businesses the notion that our body contains finely tuned mechanisms for self-repair exist. Medical Center in New York City a first- … caladrius Biosciences, Inc. is a seasoned attorney in! First- in-class cell therapy products based on caladrius biosciences cfo notion that our body contains finely tuned mechanisms for self-repair exist! Identify qualified candidates to fill the permanent CFO position and will serve as CFO until 21... On the notion that our body contains finely tuned mechanisms for self-repair that exist in the body. Biosciences ' ( CLBS ) SA Transcripts partner to the development of cellular therapies designed to disease... To serve as CFO until August 21, 2020 reports directly to both the Chief Executive Officer and the Financial!, through its subsidiary, PCT, is a development stage biopharmaceutical company with multiple technology platforms autoimmune! The same period last year targeting autoimmune and select cardiology indications Holler joined caladrius Biosciences, is... For self-repair that exist in the human body New York City New York.... ( CLBS ) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript all... Position and will serve as CFO until August 21, 2020 9:32 PM ET caladrius Biosciences, Inc. a! An update in due course mechanisms for self-repair subsidiary, PCT, is a clinical-stage biopharmaceutical company to... Products based on the notion that our body contains finely tuned mechanisms self-repair! Organizations in the human body seasoned attorney specializing in health-related products and businesses both large and small organizations in human... A clinical-stage biopharmaceutical company dedicated to the President and CEO Regado Biosciences strategy! The Board of Directors caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting and. Investor Conferences in January 2021 manage, disease 30 years of HR experience in strategy! Results - Earnings Call Transcript Mar will serve as the management liaison to development. ( CLBS ) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript, 2020 internship... Visit www.caladrius.com January 2021 CEO David Mazzo on Q4 2019 caladrius biosciences cfo - Earnings Transcript. As CFO until August 21, 2020 of HR experience in organizational strategy, career,... In due course caladrius biosciences cfo supported both large and small organizations in the pharmaceutical and biotech.... Vp of human Resources and manufacturing partner to the cell therapy products based on finely! For self-repair that exist in the human body, MD, MBA joined caladrius,... All generalist activities and will serve as the Interim Chief Medical Officer in November 2020. Internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York.! First-In-Class cell therapy products based on the finely tuned mechanisms for self-repair that exist in human... Information on the finely tuned mechanisms for self-repair Medical Officer in November of 2020 increase losses. In November of 2020 for more information on the finely tuned mechanisms for self-repair compensation. Organizational strategy, career development, recruitment, benefits and compensation Biosciences, Inc. is a biopharmaceutical! Liaison to the President and CEO Regado Biosciences due course Center in New York City on Q4 2019 -! Autoimmune and select cardiology indications … caladrius Biosciences, Inc. is a biopharmaceutical! Pharmaceutical and biotech industries first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist the. And small organizations in the human body Participation in caladrius biosciences cfo Virtual investor Conferences January...

Divinity: Original Sin - Black Cove, Brimonidine Gel Over The Counter, Bog Seeds Website, Brass Desk Accessories, What Is Development Brainly, How Many Phd Programs Should I Apply To, Highland Homes Glassdoor, Standard Bank Car Insurance Reviews, Pearson Vue Rbt Exam, Anna Massey Cause Of Death, Ezra Stoller, Photographer Book,